Navigation Links
Carterra® Inc. Selected by the La Jolla Institute of Immunology to Provide Antibody Screening and Characterization for the Coronavirus Immunotherapy Consortium (CoVIC)
Date:4/1/2020

Carterra® Inc., the world leader in high-throughput antibody screening and characterization tools, and La Jolla Institute for Immunology (LJI), announced today that they will use Carterra’s proprietary LSA™ platform to screen hundreds of antibodies in just a few days allowing CoVIC to move therapeutic candidates to the clinic as early as this summer.

La Jolla Institute for Immunology (LJI) has been awarded a $1.73 million grant by the Bill & Melinda Gates Foundation to establish a Coronavirus Immunotherapy Consortium (CoVIC) as part of the foundation’s global efforts to stem the tide of the current coronavirus outbreak, the Institute announced yesterday. Antibody therapies are often the first novel therapies advanced for an emerging infectious disease.

Headquartered at LJI, CoVIC will serve as a clearinghouse to understand which antibodies are most effective against the novel coronavirus SARS-CoV-2 and to accelerate the research pipeline to provide immunotherapeutics in order to protect vulnerable individuals from severe manifestations of COVID-19 in all parts of the world including low-resource settings.

This effort is being funded as part of the COVID-19 Therapeutics Accelerator launched in early March by the Gates Foundation, Wellcome, and Mastercard. The Accelerator provides fast and flexible funding at key stages of the development process to de-risk the pathway for drugs and biologics to prevent and treat COVID-19.

The effort is led by Erica Ollmann Saphire, Ph.D., a professor in LJI’s Center for Infectious Disease and Vaccine Research, who draws on her broad research experience guiding the development of antibody drugs and galvanizing a global research coalition that helped define which therapeutic antibodies effectively combat disease in humans infected with Ebola virus.

“We are thrilled that Carterra will provide full antibody characterization data using affinity measurements and, potentially more importantly, ultra-high resolution information of the epitopes,” says Dr. Ollmann Saphire. “Knowing how well these antibodies bind to the target is important but understanding their mechanism of action and how different antibodies can complement each other will determine what ends up in the clinic.”

Traditional antibody discovery requires a primary screen of ever-expanding antibody libraries. Only a small group of candidate antibodies are then characterized on traditional, low-throughput, low-resolution biosensor tools which provide real-time readout of the binding profile. This workflow runs the risk that potential drug candidates could be missed or that the process of candidate selection could be exceedingly long.

Carterra’s LSA is turning that model on its head by enabling the high-resolution analysis of entire libraries, combining screening and characterization into one seamless step, thereby minimizing the risk of missing a potent therapeutic candidate. The LSA’s dramatic throughput condenses months of work into days. Infectious diseases are ideal for leveraging the power of the LSA platform as evidenced in recent studies of Yellow Fever and Ebola where the LSA helped elucidate the immunity of survivors.

Additionally, the LSA platform offers investigators the most resolved view of the epitope – the location an antibody binds to its target. An epitope is an innate property that cannot be changed and must be discovered empirically. The LSA is the only technology that enables characterization of epitope binding at the full library level.

“The world is in need of a solution to COVID-19,” says Josh Eckman, Carterra’s Chief Executive Officer. “We’re honored to be the provider of high-throughput antibody screening and characterization data to CoVIC. They have the most ambitious research goals and aggressive timelines. The Carterra LSA is the right tool at the right time.”

About Carterra, Inc.
Carterra® is the leading provider of high throughput technologies designed to accelerate and improve the discovery of novel therapeutic candidates. Carterra’s LSA™ instrument, software, and consumables for monoclonal antibody (mAb) characterization deliver up to 100 times the throughput of existing platforms in 10% of the time while using only 1% of the sample required by other systems. The LSA combines patented microfluidics technology with real-time high throughput Surface Plasmon Resonance (HT-SPR) and industry-leading data analysis and visualization software to revolutionize mAb screening. Carterra, Inc. is based in Salt Lake City Utah, and has Customer Experience Centers in Dublin, California, Boston, Massachusetts, and Munich, Germany. For additional information, please visit: http://www.carterra-bio.com

About La Jolla Institute for Immunology
La Jolla Institute for Immunology is dedicated to understanding the intricacies and power of the immune system so that we may apply that knowledge to promote human health and prevent a wide range of diseases. Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading towards its goal: life without disease®.

Read the full story at https://www.prweb.com/releases/carterra_inc_selected_by_the_la_jolla_institute_of_immunology_to_provide_antibody_screening_and_characterization_for_the_coronavirus_immunotherapy_consortium_covic/prweb17016841.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. Greenphires ClinCard Technology Platform selected by Bavarian Nordic for Major Vaccine Trial
2. ExakTime’s GeoTrakker Selected for 2013 Most Innovative Product Award Program
3. SoundConnect Recently Selected by iCIMS, Inc.
4. Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation.
5. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
6. Charm Sciences ROSA 8 Minute Antibiotic Test Selected as Confirmation Test of France
7. 2013 NASA Advanced Technology Phase I Concepts Selected For Study
8. Freeslate’s Biologics Formulation System Selected by Sanofi Pasteur to Improve Efficiency of Formulation Development
9. Mytrus Electronic Informed Consent System Selected for 2013 Product Leadership Award in Clinical Trials
10. Rocky Mountain Biologicals CEO Selected to Participate in the 2013 Montana Economic Development Conference in Butte
11. Emergent Technologies Selected to Serve 50 of the World’s Most Innovative Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2020)... ... ... Reducing carbon emissions has been and will continue to be a major topic of ... reduce CO2 is something we can’t avoid. , To protect the environment, oil ... are created from recycled cooking oil or crops. Unfortunately, these sources are not sustainable. ...
(Date:5/30/2020)... ... May 29, 2020 , ... ... diagnostics, and animal health markets, has enabled Cytovale, Inc., a medical technology company ... machine learning, to achieve their first patient in (FPI) in just seven days. ...
(Date:5/28/2020)... ... May 28, 2020 , ... The Security Industry Association ... as the 2020 winners of the Women in Biometrics Awards – a ... , Biometric Update and the SIA Women in Security Forum . ...
(Date:5/21/2020)... ... , ... Experienced periodontist in Eden Prairie, MN, Dr. Andres Sanchez, offers a ... PIEZOSURGERY® technology. PIEZOSURGERY uses ultrasonic vibrations to gently cut bone in the mouth ... implants, especially when the implants need to be placed in a sensitive area of ...
Breaking Biology Technology:
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... and solutions for glioblastoma—the most common and aggressive adult brain cancer—announced today the ... PhD. Senior Fellows are charged with supporting the organization’s initiatives and overall vision. ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions LLC ... services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ... patients with severe COVID-19. This is the first study of an XPO1 inhibitor ...
Breaking Biology News(10 mins):